PositiveID Corp. develops unique medical devices and biological detection systems. The company’s primary focus is on diabetes management, rapid clinical diagnostic testing and airborne bio-threat detection.
The company announced today that it has submitted its 510(k) pre-market notification application for its iglucose mobile health system for diabetes management to the US Food and Drug Administration. Positive ID’s iglucose is a wireless communication system that facilitates diabetes management by automatically creating electronic logs and journals of blood glucose readings to help ensure patient compliance and data accuracy.
PositiveID’s iglucose automatically shares this information with family members, caregivers and, most importantly, healthcare professionals. This eliminates the burden of keeping a logbook and empowers people with diabetes to be more engaged in the self-management of their condition. It also helps the patients’ doctors to more easily judge the efficacy of the medication given to treat the patient’s diabetes.
In addition to iglucose, the company continues the development of its other diabetes management projects. These include the non-invasive Easy Check breath glucose detection device and GlucoChip, a glucose-sensing implantable microchip.
For additional information on PositiveID, please visit its website at www.PositiveIDCorp.com
About MissionIR:
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
